{"id":"202111174530","sourceId":"dow-jones","sourceName":"Global News Select","providerName":"Dow Jones","title":"Zentalis Gets FDA Fast-Track Designation for ZN-c3 in Uterine Serous Carcinoma","publishedDate":"2021-11-17T06:32:00-06:00","body":[{"type":"p","contentObject":[{"type":"text","content":"\n  By Colin Kellaher ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Zentalis Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration granted fast-track designation to ZN-c3, its product candidate for the treatment of recurrent or persistent uterine serous carcinoma in adults. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  The New York clinical-stage biopharmaceutical company said it is conducting a Phase 2 study of ZN-c3 in uterine serous carcinoma, an aggressive variant of endometrial cancer that accounts for less than 10% of all endometrial cancers but 80% of related deaths. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Write to Colin Kellaher at colin.kellaher@wsj.com ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  (END) Dow Jones Newswires","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  November 17, 2021 07:32 ET (12:32 GMT)","gated":false}],"gated":false},{"type":"text","content":"\n\nCopyright (c) 2021 Dow Jones & Company, Inc.","gated":false}]}